A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab

• Hauptverfasser: Andrew McKenzie (Verfasst von), Anthony Roberts (Verfasst von), Sourabh Malandkar (Verfasst von), Henrike Feuersenger (Verfasst von), Con Panousis (Verfasst von), Dipti Pawaskar (Verfasst von)
• Format: Buch
• Veröffentlicht: Wiley, 2022-03-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Factor XII (FXII) is the principal initiator of the plasma contact system and has proinflammatory and prothrombotic activities. This single‐center, first‐in‐human phase I study aimed to assess the safety and tolerability of single escalating doses of garadacimab, a monoclonal antibody that...